Quantitation of interferon regulatory factor transcripts in patients with acute myeloid leukemia

Supriya Perambakam, Biarou Li, Harvey Preisler

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Interferon regulatory factors IRF-1 and IRF-2, the two mutually antagonistic factors, fluctuate during the cell cycle and play an important role in normal and neoplastic growth processes. The relative levels of these two transcripts were analyzed in 5 normal and 43 acute myeloid leukemia (AML) bone marrow (BM) specimens by a semiquantitative RT-PCR method. IRF-1 and IRF-2 cDNA sequences were coamplified using primers that were designed to span regions of high homology between the genes. Each primer can anneal equally to both IRF-1 and IRF-2 sequences. Hence, the relative amount of amplified products from each cDNA species provides an estimation of proportional concentration of the RNA transcripts in the test sample. Results indicate expression of both the transcripts on all the leukemia and lymphoma cell lines tested, normal and AML BM. Significantly higher IRF-1:IRF-2 ratio was observed in normal as compared to AML BM (p = 0.007). There was no correlation with clinical factors such as FAB subtype. A single dose of amifostine or three daily doses of recombinant IL-4 were administered to 5 and 8 AML patients, respectively. The changes in the expression of these transcripts were studied prior to administration of the agent (d0) and after 3 days (d3). IL-4 treatment showed significant increase in the IRF-1:IRF-2 ratio in 4 of 8 patients (p = 0.05); amifostine treatment did not show any appreciable change.

Original languageEnglish (US)
Pages (from-to)346-351
Number of pages6
JournalCancer Investigation
Issue number4
StatePublished - Jun 21 2001
Externally publishedYes


  • AML
  • Amifostine
  • Bone marrow
  • IL-4
  • IRF-1
  • IRF-2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Quantitation of interferon regulatory factor transcripts in patients with acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this